Stock Market

Zscaler shares rise after Q2 beat, raised 2025 billings outlook

Investing | Thu, Mar 06 2025 09:15 PM AEDT

1695367561_650d4189d32c8_1692951951_64e8658fe70f4_breaking_news_600.png
Image Source: Sivastatz

Investing.com -- Zscaler Inc reported better-than-expected second-quarter results on Wednesday and raised its full-year billings outlook, sending its shares up nearly 5% in premarket trading Thursday,

The cloud security firm posted earnings per share of $0.78, exceeding analysts' estimates of $0.69. Revenue rose to $647.9 million, beating the consensus forecast of $634.4 million.

"Growing adoption of Zero Trust and AI is driving strong demand for our platform, resulting in yet another strong quarter that exceeded our guidance on both top and bottom line," said CEO Jay Chaudhry.

Zscaler reported billings of $742 million for the quarter, 3.2% ahead of consensus, with growth accelerating to 18%.

Annual recurring revenue (ARR) surpassed $2.7 billion, increasing 23% year over year, and is expected to exceed $3 billion by the end of the year. Net revenue retention (NRR) improved by one percentage point to 115% during the quarter.

"Zscaler’s FQ2’25 started to show clearer evidence that their investment in new sales talent and strategy is paying off," Bernstein analysts led by Peter Weed commented.

Zscaler (NASDAQ:ZS) now expects earnings per share of $3.04 to $3.09, for 2025, which is above Wall Street’s estimate of $2.99. The company forecast full-year revenue of $2.64 billion to $2.65 billion, below analysts' expectations of $2.69 billion.

Management raised its full-year 2025 billings growth outlook to 20.5% from 19.6%, fully reflecting the quarterly billings beat.

They also project sequential billings growth of 230 basis points in the third quarter, implying growth of 21.0% in the third quarter and 25.4% in the fourth, compared to prior consensus estimates of 22.4% and 24.5%.

"While the F3Q billings indication was slightly below consensus, the beat and raise likely increases investor confidence in the F2H ramp," Wolfe Research analysts said in a note.

Pratyush Thakur contributed to this report.

This article first appeared in Investing.com

Market Updates

Novotech Releases Hepatitis B Global Clinical Trial Landscape Report 2025

Global Insights into Hepatitis B Clinical Research: Novotech Releases 2025 Report SYDNEY--(BUSINESS WIRE)--#ClinicalTrials--Novotech, the global full-service clinical Contract ...

Business Wire | Fri, Mar 07 2025 03:05 AM AEDT

Read More
World News

Change the Lending Paradigm: A Finance Model for Success in Native Agriculture

by Skya Ducheneaux, AkiptanAkiptan began lending in 2019 and has since committed over $31M in loans to producers and nearly $1M ...

3BL | Fri, Mar 07 2025 02:00 AM AEDT

Read More
Stock Market

Truist says mobility and delivery trends tracking ahead of expectations

Investing.com -- Truist raised its price target on Uber (NYSE:UBER) to $92 from $90, citing stronger-than-expected trends in both mobility ...

Investing | Fri, Mar 07 2025 01:45 AM AEDT

Read More
World News

Building Momentum: Driving New Energy Forward in 2025 and Beyond

The global energy transition to a low-carbon future poses many challenges. There’s no silver bullet and a diverse range ...

3BL | Fri, Mar 07 2025 01:45 AM AEDT

Read More
World News

TCS Study Reveals Sustainability and Innovation Are Driving the Future of eMobility

The electric mobility (eMobility) revolution is rapidly accelerating, which presents both opportunities and challenges for a sustainable future. A recent ...

3BL | Fri, Mar 07 2025 01:45 AM AEDT

Read More